Lys⁹ for Glu⁹ substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39)

B.D. Green, M.H. Mooney, V.A. Gault, N. Irwin, C.J. Bailey, P. Harriott, B. Greer, P.R. Flatt, F.P.M. O'Harte

School of Biosciences
Aston Research Centre for Health in Ageing
College of Health and Life Sciences

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Lys⁹ for Glu⁹ substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39)'. Together they form a unique fingerprint.

Sort by
Weight
Alphabetically

Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39)

Fingerprint

Medicine & Life Sciences

Lys⁹ for Glu⁹ substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39)